Cargando…
Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A
The purpose of this study was to prepare large hollow particles (LHPs) by spray drying for pulmonary delivery of cyclosporine A (CsA), using L-Leucine (LEU) and hydroxypropyl methylcellulose (HPMC) as excipients and ammonium bicarbonate (AB) as a porogen. The prepared LHPs were spherical particles c...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537410/ https://www.ncbi.nlm.nih.gov/pubmed/37765173 http://dx.doi.org/10.3390/pharmaceutics15092204 |
_version_ | 1785113096338014208 |
---|---|
author | Huang, Yongpeng Tang, Hui Meng, Xiangyan Zhao, Zitong Liu, Yanli Liu, Dongxin Chen, Bo Zou, Zhiyun |
author_facet | Huang, Yongpeng Tang, Hui Meng, Xiangyan Zhao, Zitong Liu, Yanli Liu, Dongxin Chen, Bo Zou, Zhiyun |
author_sort | Huang, Yongpeng |
collection | PubMed |
description | The purpose of this study was to prepare large hollow particles (LHPs) by spray drying for pulmonary delivery of cyclosporine A (CsA), using L-Leucine (LEU) and hydroxypropyl methylcellulose (HPMC) as excipients and ammonium bicarbonate (AB) as a porogen. The prepared LHPs were spherical particles composed of both CsA and LEU on the surface and HPMC on the inner layer. The formulation of CsA-LEU-0.8HPMC-AB as typical LHPs showed excellent in vitro aerodynamic performance with a minimum mass median aerodynamic diameter (MMAD) of 1.15 μm. The solubility of CsA-LEU-0.8HPMC-AB was about 5.5-fold higher than that of raw CsA, and the dissolution of CsA-LEU-0.8HPMC-AB suggested that the drug was released within 1 h. The cell viability of the A549 cell line showed that CsA-LEU-0.8HPMC-AB was safe for delivering CsA to the lungs. In addition, inhalation administration of CsA-LEU-0.8HPMC-AB with the C(max) and AUC(0–∞) increasing by about 2-fold and 2.8-fold compared with the oral administration of Neoral(®) could achieve therapeutic drug concentrations with lower systemic exposure and significantly improve the in vivo bioavailability of CsA. From these findings, the LHPs, with the advantage of avoiding alveolar macrophage clearance, could be a viable choice for delivering CsA by inhalation administration relative to oral administration. |
format | Online Article Text |
id | pubmed-10537410 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-105374102023-09-29 Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A Huang, Yongpeng Tang, Hui Meng, Xiangyan Zhao, Zitong Liu, Yanli Liu, Dongxin Chen, Bo Zou, Zhiyun Pharmaceutics Article The purpose of this study was to prepare large hollow particles (LHPs) by spray drying for pulmonary delivery of cyclosporine A (CsA), using L-Leucine (LEU) and hydroxypropyl methylcellulose (HPMC) as excipients and ammonium bicarbonate (AB) as a porogen. The prepared LHPs were spherical particles composed of both CsA and LEU on the surface and HPMC on the inner layer. The formulation of CsA-LEU-0.8HPMC-AB as typical LHPs showed excellent in vitro aerodynamic performance with a minimum mass median aerodynamic diameter (MMAD) of 1.15 μm. The solubility of CsA-LEU-0.8HPMC-AB was about 5.5-fold higher than that of raw CsA, and the dissolution of CsA-LEU-0.8HPMC-AB suggested that the drug was released within 1 h. The cell viability of the A549 cell line showed that CsA-LEU-0.8HPMC-AB was safe for delivering CsA to the lungs. In addition, inhalation administration of CsA-LEU-0.8HPMC-AB with the C(max) and AUC(0–∞) increasing by about 2-fold and 2.8-fold compared with the oral administration of Neoral(®) could achieve therapeutic drug concentrations with lower systemic exposure and significantly improve the in vivo bioavailability of CsA. From these findings, the LHPs, with the advantage of avoiding alveolar macrophage clearance, could be a viable choice for delivering CsA by inhalation administration relative to oral administration. MDPI 2023-08-25 /pmc/articles/PMC10537410/ /pubmed/37765173 http://dx.doi.org/10.3390/pharmaceutics15092204 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Huang, Yongpeng Tang, Hui Meng, Xiangyan Zhao, Zitong Liu, Yanli Liu, Dongxin Chen, Bo Zou, Zhiyun Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A |
title | Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A |
title_full | Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A |
title_fullStr | Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A |
title_full_unstemmed | Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A |
title_short | Development of Large Hollow Particles for Pulmonary Delivery of Cyclosporine A |
title_sort | development of large hollow particles for pulmonary delivery of cyclosporine a |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537410/ https://www.ncbi.nlm.nih.gov/pubmed/37765173 http://dx.doi.org/10.3390/pharmaceutics15092204 |
work_keys_str_mv | AT huangyongpeng developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT tanghui developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT mengxiangyan developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT zhaozitong developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT liuyanli developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT liudongxin developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT chenbo developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea AT zouzhiyun developmentoflargehollowparticlesforpulmonarydeliveryofcyclosporinea |